[HCV protease inhibitors and drug resistance].
Treatment efficacy ofDAAs is limited in the presence of HCV mutants which revealed amino-acids substitution and drug resistance. Because of the high genetic heterogeneity of HCV and its rapid replication, monotherapy with DAA agents poses a high risk for selection of resistant variants. We review the factors that determine resistance, the methods of resistance detection and strategies to avoid the selection of resistant variants.
Katedra i Klinika Chor6b Zakainych i Hepatologii, Katedra i Klinika Chorüb Zakainych i Hepatologii Collegium Medicum im. L. Rydygiera w Bydgoszczy Uniwersytet Mikolaja Kopernika w Toruniu. kikchzak@cm.umk.pl
Małgorzata
M
Pawłowska
Anita
A
Olczak
D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000187:drug effects*; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D011480:Protease Inhibitors